Emerging anticoagulants

Bibliography

• World Health Organization. The World Health Report 2008. Primary Health Care – Now More Than Ever; 2008. Available from: http://www.who.int/whr/2008/whr08_en.pdf [Cited 11 September 2010]
   Google Scholar
• World Health Organization. Global Strategy on Diet, Physical Activity and Health – Cardiovascular Disease: Prevention and Control; 2010. Available from: http://www.who.int/dietphysicalactivity/publications/facts/cvd/en/index.html [Cited 11 September 2010]
   Google Scholar
• Chockalingam A, Balaguer-Vintro I, Achutti A, The World Heart Federation's white book: impending global pandemic of cardiovascular diseases: challenges and opportunities for the prevention and control of cardiovascular diseases in developing countries and economies in transition. Can J Cardiol 2000;16(2):227-9
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a ‘call to action’ for vascular medicine specialists. J Thromb Haemost 2007;5(8):1607-9
   PubMed Web of Science ®Google Scholar
• Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J 2005;26(1):3-4
   PubMed Web of Science ®Google Scholar
• Sobieszczyk P, Fishbein MC, Goldhaber SZ. Acute pulmonary embolism: don't ignore the platelet. Circulation 2002;106(14):1748-9
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Hylek E, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):160S-198S
   PubMed Web of Science ®Google Scholar
• Krishnaswamy A, Lincoff AM, Cannon CP. The use and limitations of unfractionated heparin. Crit Pathw Cardiol 2010;9(1):35-40
   PubMedGoogle Scholar
• Sasisekharan R, Shriver Z. From crisis to opportunity: a perspective on the heparin crisis. Thromb Haemost 2009;102(5):854-8
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):340S-380S
   PubMed Web of Science ®Google Scholar
• Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86(4):1368-73
   PubMed Web of Science ®Google Scholar
• Nenci GG. Low molecular weight heparins: are they interchangeable? No. J Thromb Haemost 2003;1(1):12-13
   PubMed Web of Science ®Google Scholar
• Hirsh J, Bauer KA, Donati MB, Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):141S-159S
   PubMed Web of Science ®Google Scholar
• Adiguzel C, Jeske WP, Hoppensteadt D, Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Clin Appl Thromb Hemost 2009;15(2):137-44
   PubMed Web of Science ®Google Scholar
• Jeske WP, Walenga JM, Hoppensteadt DA, Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 2008;34(01):74-85
   PubMed Web of Science ®Google Scholar
• Stafford DW. The vitamin K cycle. J Thromb Haemost 2005;3(8):1873-8
   PubMed Web of Science ®Google Scholar
• Visser LE, van Schaik RH, van Vliet M, The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004;92(1):61-6
   PubMed Web of Science ®Google Scholar
• Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335(8):540-6
   PubMed Web of Science ®Google Scholar
• Palareti G, Leali N, Coccheri S, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348(9025):423-8
   PubMed Web of Science ®Google Scholar
• Denas G, Marzot F, Offelli P, Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. J Thromb Thrombolysis 2009;27(3):340-7
   PubMed Web of Science ®Google Scholar
• Denas G, Cucchini U, Iliceto S, Pengo V. An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0. Thromb Haemost 2009;101(2):410-11
   PubMed Web of Science ®Google Scholar
• Crowther MA, Ageno W, Garcia D, Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009;150(5):293-300
   PubMed Web of Science ®Google Scholar
• Pengo V, Cucchini U, Denas G, Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009;119(22):2920-7
   PubMed Web of Science ®Google Scholar
• Douketis JD, Berger PB, Dunn AS, The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):299S-339S
   PubMed Web of Science ®Google Scholar
• Flaker GC, Gruber M, Connolly SJ, Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006;152(5):967-73
   PubMed Web of Science ®Google Scholar
• Bousser MG, Bouthier J, Buller HR, Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008;371(9609):315-21
   PubMed Web of Science ®Google Scholar
• Lazo-Langner A, Rodger MA, Wells PS. Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery. Clin Appl Thromb Hemost 2009;15(3):316-26
   PubMed Web of Science ®Google Scholar
• Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133(Suppl 6):234S-256S
   PubMed Web of Science ®Google Scholar
• Harenberg J, Vukojevic Y, Mikus G, Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 2008;6(5):890-2
   PubMed Web of Science ®Google Scholar
• Buller HR, Cohen AT, Davidson B, Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357(11):1094-104
   PubMed Web of Science ®Google Scholar
• Harenberg J, Jorg I, Vukojevic Y, Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 2008;64(6):555-63
   PubMed Web of Science ®Google Scholar
• Trellu M, Perez Y, Ortiz J, Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects [abstract]. J Thromb Haemost 2007;5(Suppl 2): P-T-678
   Google Scholar
• Buller H, Destors JM, Gallus A, Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX study): safety, efficacy, and reversibility by avidin. Blood (ASH Annual Meeting Abstracts) 2008;112(18): abstract 32
   Google Scholar
• Savi P, Herault JP, Duchaussoy P, Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008;6(10):1697-706
   PubMed Web of Science ®Google Scholar
• Paty I, Trellu M, Destors JM, Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010;8(4):722-9
   PubMed Web of Science ®Google Scholar
• Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009;102(5):811-15
   PubMed Web of Science ®Google Scholar
• Guertin KR, Choi YM. The discovery of the factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem 2007;14(23):2471-81
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Antman EM, Widimsky P, Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374(9692):787-95
   PubMed Web of Science ®Google Scholar
• Viskov C, Just M, Laux V, Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost 2009;7(7):1143-51
   PubMed Web of Science ®Google Scholar
• Dubruck C, Karimi-Anderesi N, Lunven C, Pharmacokinetics of a new, ultra-low molecular weight heparin, semuloparin (AVE5026), in healthy subjects. Results from the first phase I studies [poster 1073]. 51st ASH Annual Meeting; 2009. Available from: http://ash.confex.com/ash/2009/webprogram/Paper22065.html [Cited 23 June 2010]
   Google Scholar
• Lassen MR, Dahl OE, Mismetti P, AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose-ranging study. J Thromb Haemost 2009;7(4):566-72
   PubMed Web of Science ®Google Scholar
• Turpie AG, Agnelli G, Fisher W, Benefit-to-risk profile of the ultra-low-molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE): a meta-analysis of 3 major orthopaedic surgery studies [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC332
   Google Scholar
• Fisher W, Agnelli G, George D, The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after hip fracture surgery [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):P330
   Google Scholar
• Fisher W, Agnelli G, George D, Extended venous thromboembolism (VTE) prophylaxis after hip fracture surgery with the ultra-low-molecular-weight heparin (ULMWH) semuloparin [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC681
   Google Scholar
• Mouret P, Agnelli G, Fisher W, The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after elective hip replacement surgery [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC316
   Google Scholar
• Lassen MR, Agnelli G, Fisher W, The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after elective knee replacement surgery [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC331
   Google Scholar
• Hoppensteadt DA, Jeske W, Walenga JM, Fareed J. AVE5026: a new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis [abstract]. J Clin Oncol 2008;26(Suppl):14653
   Google Scholar
• Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol 2010;30(3):382-7
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Weitz JI. Otamixaban in acute coronary syndromes. Lancet 2009;374(9692):762-4
   PubMed Web of Science ®Google Scholar
• Chan MY, Rusconi CP, Alexander JH, A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 2008;6(5):789-96
   PubMed Web of Science ®Google Scholar
• Chan MY, Cohen MG, Dyke CK, Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008;117(22):2865-74
   PubMed Web of Science ®Google Scholar
• Cohen MG, Drew AP, Rossi JS, Factor IXa inhibition with REG1 provides rapid onset, stable and actively controlled anticoagulation during PCI [abstract]. J Am Coll Cardiol 2010;55(10A):, A206.E1940
   Google Scholar
• Cohen MG, Purdy DA, Rossi JS, First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010;122(6):614-22
   PubMed Web of Science ®Google Scholar
• Linhardt RJ. Chemical and enzymatic methods for the depolymerization and modification of heparin. Carbohydrates-synthetic methods and applications in medicinal chemistry. Kodansha/VCH Publishers, Tokyo/Weinheim; 1992. p. 385-401
   Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-30
   PubMed Web of Science ®Google Scholar
• Rao SV, Melloni C, Myles-Dimauro S, Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. Circulation 2010;121(15):1713-21
   PubMed Web of Science ®Google Scholar
• Melloni C, Fier I, Roach J, Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial. Am Heart J 2009;158(5):726-33
   PubMed Web of Science ®Google Scholar
• Verhamme P, Pakola S, Jensen TJ, Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther 2010;32(6):1205-20
   PubMed Web of Science ®Google Scholar
• Verhamme P, Verhaeghe R, Ageno W, Single intravenous administration of TB-402 for the prophylaxis of VTE after total knee replacement surgery [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):P509
   Google Scholar
• Mohri M, Sugimoto E, Sata M, Asano T. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation – a comparison with other anticoagulants. Thromb Haemost 1999;82(6):1687-93
   PubMed Web of Science ®Google Scholar
• Sadler JE. Thrombomodulin structure and function. Thromb Haemost 1997;78(1):392-5
   PubMed Web of Science ®Google Scholar
• Mohri M, Suzuki M, Sugimoto E, Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma. Thromb Haemost 1998;80(6):925-9
   PubMed Web of Science ®Google Scholar
• Mohri M. ART-123: recombinant human soluble thrombomodulin. Cardiovasc Drug Rev 2000;18(4):312-25
   Google Scholar
• Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82(2):718-21
   PubMed Web of Science ®Google Scholar
• Kearon C, Comp P, Douketis J, Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005;3(5):962-8
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007;98(1):155-62
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36(2):386-99
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009;48(1):1-22
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5(11):2178-85
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370(9591):949-56
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Davidson BL, Comp PC, Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24(1):1-9
   PubMed Web of Science ®Google Scholar
• Huo M. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomized trial. Presented at 15th Congress of the European Hematology Association; 10 – 13 June 2010; Barcelona, Spain
   Google Scholar
• Schulman S, Kearon C, Kakkar AK, Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24):2342-52
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GY, Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• Mueck W, Borris LC, Dahl OE, Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100(3):453-61
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris L, Dahl OE, Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4(1):121-8
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Dahl OE, A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114(22):2374-81
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358(26):2765-75
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358(26):2776-86
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372(9632):31-9
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373(9676):1673-80
   PubMed Web of Science ®Google Scholar
• The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159(3):340-47 e1
   PubMed Web of Science ®Google Scholar
• Lassen MR, Davidson BL, Gallus A, The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007;5(12):2368-75
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361(6):594-604
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375(9717):807-15
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, Randomized double-blind comparison of apixaban and enoxaparin for thromboprophylaxis after hip replacement: the ADVANCE-3 trial [abstract]. Pathophysiol Haemost Thromb 2009/2010;37(Suppl 1):OC356
   Google Scholar
• Connolly S. A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES). Presented at European Society of Cardiology 2010 Congress; 31 August 2010; Stockholm, Sweden
   Google Scholar
• Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Weitz JI, Connolly SJ, Patel I, Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104(3):633-41
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Davidson BL, A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101(1):68-76
   PubMed Web of Science ®Google Scholar
• Garcia D, Milner PG, Canafax DM, Ellis DJ. Results of the EmbraceAC Trial: A Head-to-Head Comparison of Warfarin with Tecarfarin, A New Anticoagulant. 51st ASH Annual Meeting and Exposition. American Society of Hematology, New Orleans, LA; 2009
   Google Scholar
• Buller HR, Lensing AW, Prins MH, A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112(6):2242-7
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374(9683):29-38
   PubMed Web of Science ®Google Scholar
• Alexander JH, Becker RC, Bhatt DL, Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119(22):2877-85
   PubMed Web of Science ®Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119(23):3028-35
   PubMed Web of Science ®Google Scholar
• Newby LK, LaPointe NM, Chen AY, Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113(2):203-12
   PubMed Web of Science ®Google Scholar